A Phase 2/3 interventional study of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1), sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company. Recruiting at 6 sites in 2 countries. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company (part of BridgeBio) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Hypocalcemia with a site in United States — 2 open to participants now, 5 under way, 2 of them phase 3. Hypocalcemia · United States.
Among the 30 studies in Hypocalcemia with a site in United States, this one is the 16th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 2/3, and was the 30th registered.
98 studies on the registry are indexed under Hypocalcemia; 16 are open to participants now.
Browse Hypocalcemia studies →2 of the 30 studies in Hypocalcemia with a site in United States are open now. Recruiting first, the newest first:
Peerbridge Health, Inc · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Hypocalcemia studies recruiting now, 8 (73%) set no upper age limit and 2 (18%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 0 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 8 · Phase 4 3
First in 1976; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 84 across 66 interventional studies indexed under Hypocalcemia.
Median enrollment 36 across the 25 interventional studies, 273 across the 5 observational. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Calcilytix Therapeutics, Inc., a BridgeBio company, one of the names counted as BridgeBio. Under that name alone:
Calcilytix Therapeutics, Inc., a BridgeBio company is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
BridgeBio has 3 studies filed under Hypocalcemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Hypocalcemia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive encaleret dosing in Period 1 (6 days), Period 2 (20 weeks) and Period 3 (4 weeks). Following completion of Period 3, participants will have the option to enter a long-term extension (LTE) to continue encaleret for an additional approximately 24 months or until the sponsor decides to end the study, whichever occurs first.
Drug: Encaleret
Oral tablets, age-appropriate pediatric formulation (currently under development).
Period 1: Maximum Plasma Concentration (Cmax) of Encaleret and Metabolites M1, and M3
Time frame: 5 days
Period 1: Area Under the Plasma Concentration-time Curve (AUC) of Encaleret and Metabolites M1, and M3
Time frame: 5 days
Period 3: Number of Participants with Albumin-corrected Blood Calcium (cCa) and Urinary Calcium (UCa) Excretion Response
Time frame: Week 25
Period 1: Change from Baseline in Blood cCa
Time frame: Baseline up to Day 5
Period 1: Change from Baseline in Blood Intact Parathyroid Hormone (iPTH) Concentration
Time frame: Baseline up to Day 5
Period 1: Change from Baseline in Blood Phosphate Concentration
Time frame: Baseline up to Day 5
Period 1: Change from Baseline in Blood 1,25-(OH)2 Vitamin D Concentration
Time frame: Baseline up to Day 5
Period 1: Change from Baseline in Blood Magnesium Concentration
Time frame: Baseline up to Day 5
Period 1: Change from Baseline in 24-hour UCa in Toilet Trained Participants
Time frame: Baseline up to Day 5
Period 1: Change from Baseline in Spot Ratio of UCa/Urinary Creatinine (UCr) In Non-toilet Trained Participants
Time frame: Baseline up to Day 5
Period 3: Number of Participants with Blood iPTH Within the Reference Range
Time frame: Week 25 (post-dose)
Period 3: Number of Participants with Blood Phosphate Within the Reference Range
Time frame: Week 25
Period 3: Number of Participants with Blood Magnesium Within the Reference Range
Time frame: Week 25
Period 3: Number of Participants with Blood 1,25-(OH)2 Vitamin D Within the Reference Range
Time frame: Week 25
Periods 1, 2, and 3: Change from Baseline in Short Form-10 Health Survey for Children (SF-10) in Participants Aged ≥6 Years
Time frame: Baseline up to Week 25
Periods 1, 2, and 3: Dose of Calcium Supplements and/or Active Vitamin D Analogs Used as Rescue Therapy
Time frame: 25 weeks
Periods 1, 2, and 3: Dosing Frequency of Calcium Supplements and/or Active Vitamin D Analogs Used as Rescue Therapy
Time frame: 25 weeks
Periods 1, 2, 3, and LTE: Number of Participants with Adverse Events (AEs) and Serious AEs (SAEs)
Time frame: 145 weeks
LTE: Change from Baseline in Blood cCa
Time frame: Baseline up to 145 weeks
LTE: Change from Baseline in Blood iPTH Concentration
Time frame: Baseline up to 145 weeks
LTE: Change from Baseline in Blood Phosphate Concentration
Time frame: Baseline up to 145 weeks
LTE: Change from Baseline in Blood 1,25-(OH)2 Vitamin D Concentration
Time frame: Baseline up to 145 weeks
LTE: Change from Baseline in Blood Magnesium Concentration
Time frame: Baseline up to 145 weeks
LTE: Change from Baseline in 24-hour UCa In Toilet Trained Participants
Time frame: Baseline up to 145 weeks
LTE: Change from Baseline in Spot Ratio of UCa/UCr In Non-toilet Trained Participants
Time frame: Baseline up to 145 weeks
LTE: Change from Baseline in SF-10 in Participants Aged ≥6 Years
Time frame: Baseline up to 145 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Encaleret
Calcilytix Therapeutics, Inc., a BridgeBio company →